1. Evolution of Treatment Strategies Targeting IL-23 for Psoriasis

3. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Overview of the Pathogenesis and Treatment of Psoriasis

5. Evolution in the Understanding of the Pathogenesis of Psoriasis

6. Role of IL-23/IL-17 Axis as the Main Pathogenetic Pathway in Psoriasis

7. Key Targets and Development of Immunotherapies: Regulatory Approval

8. Key Targets and Development of Immunotherapies: EMA Approvals

9. Challenges and Limitations of IL-17 Agents Despite High Efficacy

10. Structure of p40 Cytokines and Targeted Agents

11. Advantages of Blocking IL-23

12. Guselkumab vs Adalimumab: VOYAGE 1 Study

13. Patient-Reported Improvements in HRQoL in VOYAGE 1

14. VOYAGE 1: Data for 2 Years of Exposure to Guselkumab and Nonresponder Imputation

15. Guselkumab Maintenance and Withdrawal: VOYAGE 2

16. Guselkumab in Patients With Inadequate Response to Ustekinumab: NAVIGATE

17. Other IL-23p19 Inhibitors in the Pipeline

18. Tildrakizumab: reSURFACE 1 and reSURFACE 2

19. Safety of Biologics for Psoriasis

20. Safety of Biologics for Psoriasis: Infections and IBD

21. Advantages of Selective IL-23 Inhibition: Clinical Considerations

22. Limitations of Selective IL-23 Inhibition: Areas for Further Investigation

23. Clinician Perspectives on Use of Selective IL-23 Inhibitors

24. Low Incidence of Serious Infections After 2 Years of Exposure to Selective IL-23 Inhibition

25. Clinician Perspectives on Real-World Use of Guselkumab

26. Concluding Remarks

27. Abbreviations

28. Abbreviations (cont)